DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-08-31

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00139191

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Squamous Cell Carcinoma
Carcinoma of Head and/or Neck

First Posted Date: 2005-08-31

Last Posted Date: 2008-06-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00139243

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Advanced Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
SSCHN

First Posted Date: 2005-08-31

Last Posted Date: 2008-06-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00139269

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma
Carcinoma of Head/Neck

First Posted Date: 2005-08-31

Last Posted Date: 2008-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00139230

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

First Posted Date: 2005-08-30

Last Posted Date: 2013-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT00137774

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Avastin and Taxotere for Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2005-08-30

Last Posted Date: 2018-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42

Registration Number: NCT00137813

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Drug: OSI-774 (Tarceva)

First Posted Date: 2005-08-30

Last Posted Date: 2020-04-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 82

Registration Number: NCT00137800

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Cisplatin
Drug: Irinotecan
Drug: Celecoxib
Procedure: Radiation Therapy
Procedure: Esophagectomy

First Posted Date: 2005-08-30

Last Posted Date: 2017-09-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00137852

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Phase 2

Completed

Conditions: Metastatic Pancreatic Carcinoma

First Posted Date: 2005-08-30

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00137761

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

First Posted Date: 2005-08-30

Last Posted Date: 2011-12-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00137826

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy